JP2020527132A5 - - Google Patents

Download PDF

Info

Publication number
JP2020527132A5
JP2020527132A5 JP2019571337A JP2019571337A JP2020527132A5 JP 2020527132 A5 JP2020527132 A5 JP 2020527132A5 JP 2019571337 A JP2019571337 A JP 2019571337A JP 2019571337 A JP2019571337 A JP 2019571337A JP 2020527132 A5 JP2020527132 A5 JP 2020527132A5
Authority
JP
Japan
Prior art keywords
disease
composition according
seq
myelin
leukodystrophy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019571337A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020527132A (ja
JP7538602B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/041636 external-priority patent/WO2019014342A1/en
Publication of JP2020527132A publication Critical patent/JP2020527132A/ja
Publication of JP2020527132A5 publication Critical patent/JP2020527132A5/ja
Application granted granted Critical
Publication of JP7538602B2 publication Critical patent/JP7538602B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019571337A 2017-07-11 2018-07-11 ミエリン障害を治療するための組成物および方法 Active JP7538602B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762531251P 2017-07-11 2017-07-11
US62/531,251 2017-07-11
PCT/US2018/041636 WO2019014342A1 (en) 2017-07-11 2018-07-11 COMPOSITIONS AND METHODS FOR TREATING MYELIN DISEASES

Publications (3)

Publication Number Publication Date
JP2020527132A JP2020527132A (ja) 2020-09-03
JP2020527132A5 true JP2020527132A5 (cg-RX-API-DMAC7.html) 2023-02-13
JP7538602B2 JP7538602B2 (ja) 2024-08-22

Family

ID=65001812

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019571337A Active JP7538602B2 (ja) 2017-07-11 2018-07-11 ミエリン障害を治療するための組成物および方法

Country Status (9)

Country Link
US (1) US20200230205A1 (cg-RX-API-DMAC7.html)
EP (1) EP3651785B1 (cg-RX-API-DMAC7.html)
JP (1) JP7538602B2 (cg-RX-API-DMAC7.html)
KR (1) KR102772298B1 (cg-RX-API-DMAC7.html)
CN (1) CN111093684A (cg-RX-API-DMAC7.html)
AU (2) AU2018301399B2 (cg-RX-API-DMAC7.html)
CA (1) CA3064463A1 (cg-RX-API-DMAC7.html)
ES (1) ES3056700T3 (cg-RX-API-DMAC7.html)
WO (1) WO2019014342A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022212872A1 (en) * 2021-04-02 2022-10-06 Case Western Reserve University Methods and compositions for accelerating oligodendrocyte maturation
AU2024373065A1 (en) * 2023-11-01 2026-05-21 Biocells (Beijing) Biotech Co., Ltd. Polypeptide derivative, pharmaceutical composition thereof and use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4731058A (en) 1986-05-22 1988-03-15 Pharmacia Deltec, Inc. Drug delivery system
US5670617A (en) 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
ATE159548T1 (de) 1990-11-13 1997-11-15 Immunex Corp Bifunktionelle wählbare fusionsgene
US6063630A (en) 1991-11-05 2000-05-16 Transkaryotic Therapies, Inc. Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5368562A (en) 1993-07-30 1994-11-29 Pharmacia Deltec, Inc. Systems and methods for operating ambulatory medical devices such as drug delivery devices
GB9718609D0 (en) 1997-09-02 1997-11-05 Imp College Innovations Ltd Fusion protein
CA2417454A1 (en) 2000-07-31 2002-02-07 Active Motif Peptide-mediated delivery of molecules into cells
BRPI0616465A2 (pt) * 2005-09-29 2011-06-21 Sanofi Aventis derivados de fenil-[1,2,4]-oxadiazol-5-ona com grupo fenila, bem como seu uso, composição farmacêutica compreendo os mesmos e processo de preparação da referida composição farmacêutica
CA3233345A1 (en) * 2012-04-09 2013-10-17 Case Western Reserve University Compositions and methods for inhibiting the activity of lar family phosphatases
US10258672B2 (en) * 2014-10-09 2019-04-16 Case Western Reserve University Compositions and methods of treating root avulsion injury

Similar Documents

Publication Publication Date Title
Schirò et al. A brief overview on BDNF-Trk pathway in the nervous system: a potential biomarker or possible target in treatment of multiple sclerosis?
Lazdon et al. Microglia and Parkinson's disease: footprints to pathology
Govoni et al. Time is motor neuron: therapeutic window and its correlation with pathogenetic mechanisms in spinal muscular atrophy
Lindvall et al. Stem cells in human neurodegenerative disorders—time for clinical translation?
Gerards et al. Leigh syndrome: Resolving the clinical and genetic heterogeneity paves the way for treatment options
Collier et al. Therapeutic potential of nerve growth factors in Parkinson’s disease
Pezet et al. Brain-derived neurotrophic factor as a drug target for CNS disorders
US6776984B1 (en) Induced regeneration and repair of damaged neurons and nerve axon myelin
Nagahara et al. Potential therapeutic uses of BDNF in neurological and psychiatric disorders
Alam et al. New insights into the role of fibroblast growth factors in Alzheimer’s disease
JP2016517884A5 (cg-RX-API-DMAC7.html)
HRP20151409T1 (hr) Lijeäśenje sinukleinopatija
JP2018531965A5 (cg-RX-API-DMAC7.html)
Daimon et al. The role of Thyrotropin Releasing Hormone in aging and neurodegenerative diseases
Rodrigues et al. Challenges and promises in the development of neurotrophic factor-based therapies for Parkinson’s disease
Dhanushkodi et al. A single intramuscular injection of rAAV‐mediated mutant erythropoietin protects against MPTP‐induced parkinsonism
Vanhoof‐Villalba et al. Pharmacogenetics of KCNQ channel activation in 2 potassium channelopathy mouse models of epilepsy
Zuccaro et al. Motor neuron diseases and neuroprotective peptides: a closer look to neurons
Ho Clearance pathways for α‐synuclein in Parkinson's disease
JP2012522005A (ja) 神経損傷および神経変性疾患後の神経学的転帰を改善する方法
Zhang et al. Neuritin inhibits astrogliosis to ameliorate diabetic cognitive dysfunction
JP2021534206A5 (cg-RX-API-DMAC7.html)
JP2021532155A5 (cg-RX-API-DMAC7.html)
WO2008057609A4 (en) Methods of treating neuronal disorders using mntf peptides and analogs thereof
Titsworth et al. Differential expression of sPLA2 following spinal cord injury and a functional role for sPLA2‐IIA in mediating oligodendrocyte death